

Equitable Resilience Fund

Monthly Report – March 2019

Comments from your Chief Investment Officer

Equity markets continued performing well through March. Commentary from members of the Federal Reserve's FOMC suggests U.S. monetary policy is likely to remain accommodative for the foreseeable future. Incoming data from China suggests growth in that economy is already responding positively to recent stimulus. Continental Europe remains the primary area of concern where cyclical and market indicators suggest the region may already be in recession; the 10-year German government bond is again trading with a negative yield.

The recovery in the equity markets continues to be led by the technology sectors, with companies benefiting from the growth in cloud computing performing especially well. As a result, some of the largest contributors to this month's performance came from your holdings in Cadence Design Systems, Synopsis and Nvidia. Outside of the computing space, medical technology, led by Edwards Life sciences, also performed well.


Once again, we have trimmed a few of your larger holdings, rebalancing the proceeds into some of your smaller investments. As a result, your largest single investment is now Roper Technologies representing approximately 3.5% of your fund's value.

NAV since inception



Net Asset Value Metrics														EUR Class	
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Last NAV	YTD	
2019	6.48%	6.02%	3.38%										135.17	16.70%	
2018	6.68%	0.08%	-4.96%	2.12%	6.70%	-2.64%	-0.84%	6.17%	-0.51%	-11.74%	-1.46%	-7.23%	115.83	-9.02%	
2017	1.96%	3.06%	1.22%	2.20%	2.74%	-0.48%	2.60%	-0.75%	2.86%	6.24%	3.12%	-2.50%	127.32	24.35%	
2016			0.51%	-0.14%	-0.44%	0.83%	4.95%	-0.36%	-0.39%	-4.19%	0.73%	1.09%	102.39	2.39%	
Annualized return since inception														10.28%	

Country Allocation



- UNITED STATES ■ FRANCE
- NETHERLANDS ■ AUSTRALIA
- SWITZERLAND ■ DENMARK
- CANADA

Top 10 Holdings

Roper Technologies	3.49%
Nvidia	3.45%
Microsoft	3.43%
Automatic Data Processing	3.35%
Intuitive Surgical	3.32%
Cisco Systems	3.30%
Apple	3.15%
Intel	3.13%
Intuit	3.04%
Kering	3.00%

Industry Exposure

Financial Services	12.40%
Telecommunications	10.34%
Software	9.27%
Medical Technology	8.54%
Microelectronic Manufacturing	7.81%
Medical Products	7.77%
Luxury Goods	5.99%
Cyber Security	4.87%
Consulting	4.40%
Microelectronic Equipment	3.98%
Diversified Manufacturing	3.49%
Simulation Software	3.22%
Consumer Electronics	3.15%
Insurance	2.81%
Retail	2.80%
Pharmaceuticals	2.48%
Cosmetics	2.41%
Chemicals	2.27%
Publishing	1.99%
Cash	0.001%

Portfolio Characteristics*

Average market. Cap (USD bn)	162.6	Equity Ratio	45.34
Number of Holdings	39	Net Debt/ Op. Cash Flow	0.04
Sales Growth (5yr)	13%	EPS Growth (5yr)	39%

*Weighted average of portfolio

Key fund facts

The Fund aims to deliver capital growth by investing in the equities of resilient, conservatively financed, well managed companies with a proven track record of innovation and growth.

Fund Details		ISIN: GB00BDD1KV12			
Fund Type	UCITS OEIC	Launch Date	29th February 2016	Min. Investment	GBP 10,000
Management Charge*	0.70%	Depositary	HSBC	Min. Further Investment	GBP 5,000
Subscription Charge	0.00%	Auditor	PricewaterhouseCoopers (PWC)	Share Class Availability	NOK, EUR, GBP, USD
Redemption Charge	0.00%	Dealing	Daily (11:00am, UK time)	Fund Domicile	UK
OCF**	1.30%	Pricing	Daily (15:00pm, UK time)	AUM (GBP)	130 million

*A management fee of 0.7% is charged only on AUM below £350 million. A performance fee of 10% of returns, in excess of the high water mark, is charged only on AUM above £350 million.

** Ongoing Charges to the Fund, as specified in the Key Investor Information Document (KIID) for the specific share class.

Disclaimer:

These materials contain preliminary information that is subject to change and is not intended to be complete or to constitute all the information necessary to adequately evaluate the consequences of making any investment.

This document is being provided solely for informational purposes. The value of an investment may fall or rise. All investments involve risk and past performance is not a guide to future returns. Equitile offers no guarantee against loss or that investment objectives will be achieved.

Equitile does not offer investment advice. Please read the Key Investor Information Document, Prospectus and any other offer documents carefully and consult with your own legal, accounting, tax and other advisors in order to independently assess the merits of an investment. Investors and any potential investors should be aware of local laws governing investments and should read all the relevant documents including any reports and accounts and scheme particulars as appropriate.

The State of the origin of the Fund is the United Kingdom and the Fund is authorised and regulated by the UK Financial Conduct Authority. This document may only be distributed in or from Switzerland to qualified investors within the meaning of Art. 10 Para. 3, 3bis and 3ter CISA. In Switzerland, the Representative is ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zürich, whilst the Paying agent is Aquila & Co. AG, Bahnhofstrasse 28a, CH – 8001 Zurich. In respect of the units distributed in Switzerland, the competent Courts shall be at the registered office of the Representative in Switzerland. The Basic documents of the Fund as defined in Art. 13a CISO as well as the annual and, if applicable, semi-annual reports may be obtained free of charge at the office of the representative.



Equitile Investments Ltd is authorised and regulated by the UK Financial Conduct Authority.